Beam Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BEAM Nasdaq 2830 beamtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Beam Therapeutics Inc.

Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3 - Oct 30th, 2026 11:05 pm
3 Promising Genomics Stocks to Add to Your Portfolio Now - Oct 30th, 2026 7:09 am
Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and Intellia - Oct 29th, 2026 9:30 am
Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Oct 29th, 2026 7:00 am
Why Beam Therapeutics Stock Is Up 15.6% And What's Next - Oct 29th, 2026 4:14 am
Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last? - Oct 29th, 2026 1:50 am
BEAM Stock Climbs On First Look At One-Time GSDIa Gene Fix; H.C. Wainwright Sees Further 200% Upside - Oct 27th, 2026 1:21 pm
Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance - Oct 27th, 2026 9:05 am
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress - Oct 27th, 2026 5:00 am
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? - Oct 17th, 2026 7:20 pm
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress - Oct 13th, 2026 5:00 am
Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative - Sep 30th, 2026 7:23 pm
Beam sues 2 biotechs, alleging theft of base editing trade secrets - Sep 29th, 2026 12:34 pm
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity - Sep 29th, 2026 7:00 am
As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock - Sep 28th, 2026 3:02 pm
Cathie Wood Makes $64 Million Bet on Two Stocks - Sep 28th, 2026 1:11 pm
Anthropic AI Discovery Gene-Editing Stocks Falling - Sep 24th, 2026 6:46 am
Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows - Sep 23rd, 2026 7:14 pm
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon - Sep 23rd, 2026 6:22 am